Astra Zeneca
Subscribe to Astra Zeneca

The Lead

AstraZeneca reviewing psoriasis drug following suicide concerns

June 2, 2015 4:10 pm | by Andy Szal, Digital Reporter | News | Comments

The drug — named brodalumab — led to suicidal thoughts among trial patients, which could result in regulators attaching a warning label to the product.

Medicare Contrast in Generic, Brand Prescribing

May 4, 2015 11:21 am | by Lauran Neergaard, AP Medical Writer | News | Comments

The most-used medicines in Medicare's prescription drug program are generics, but the program...

Innate Pharma and AstraZeneca Announce Global Agreement

April 30, 2015 10:53 am | by Innate Pharma SA | News | Comments

Innate Pharma SA today announced that it has signed a co-development and commercialization...

AstraZeneca Profit Falls as Patent Expires on Heartburn Drug

April 24, 2015 10:43 am | by The Associated Press | News | Comments

Anglo-Swedish drug-maker AstraZeneca PLC reported a 7 percent fall in net profit for the first...

View Sample

FREE Email Newsletter

Nektar Recieves $100M Milestone from AstraZeneca

April 6, 2015 12:16 pm | by Nektar Therapeutics | News | Comments

The cash payment under the Nektar-AstraZeneca agreement was triggered by the first commercial sale of MOVANTIK (naloxegol) in the U.S. 

In Alzheimer's Mice, Memory Restored With Cancer Drug

April 1, 2015 1:01 pm | by Yale University | News | Comments

Memory and as well as connections between brain cells were restored in mice with a model of Alzheimer's given an experimental cancer drug.

AstraZeneca Joins Genomics England Consortium

March 26, 2015 8:03 am | News | Comments

AstraZeneca today announced that it has joined a public-private consortium with Genomics England to accelerate the development of new diagnostics and treatments arising from the 100,000 Genomes Project.


AstraZeneca to Collaborate With the Harvard Stem Cell Institute in Diabetes

March 25, 2015 8:45 am | News | Comments

AstraZeneca has entered into a five-year research collaboration with the Harvard Stem Cell Institute (HSCI) to adapt a technique that creates human beta cells from stem cells for use in screens of AstraZeneca’s compound library in the search for new treatments for diabetes.

Daiichi Sankyo Signs Agreement with AstraZeneca to Co-Commercialize MOVANTIK in the US

March 19, 2015 8:18 am | News | Comments

Under the terms of the agreement, Daiichi Sankyo will pay a $200M up-front fee and subsequent sales-related payments of up to $625M. AstraZeneca will be responsible for manufacturing, will book all sales and will make sales-related commission payments to Daiichi Sankyo.

AstraZeneca Completes Acquisition of Actavis’ Respiratory Products

March 3, 2015 8:05 am | News | Comments

AstraZeneca today announced that it has completed the transaction to acquire the rights to Actavis’ branded respiratory business in the US and Canada.

Survey: Clinical Trial Sponsors Show Improvement

March 2, 2015 11:19 am | by Andy Szal, Digital Reporter | News | Comments

Pharmaceutical companies sponsoring clinical trials showed strong improvement in their relationships with global investigative sites, according a recent survey.

Heat Blamed for FluMist's Failure Against Swine Flu

February 27, 2015 8:25 am | by MIKE STOBBE, AP Medical Writer | News | Comments

The makers of the nasal spray version of the flu vaccine say now they know why it has failed to protect young U.S. children against swine flu — fragile doses got too warm.


US District Court Decision in PULMICORT RESPULES® Patent Litigation

February 17, 2015 8:44 am | News | Comments

AstraZeneca has announced that the US District Court for the District of New Jersey ruled US Patent No. 7,524,834 (“the ‘834 patent”), protecting PULMICORT RESPULES in the US, is invalid.

AstraZeneca to Pay $7.9M Over Kickback Allegations

February 11, 2015 1:38 pm | News | Comments

The Justice Department says AstraZeneca will pay $7.9 million to settle allegations it engaged in a kickback scheme involving drugs such as heartburn medicines Nexium and Prilosec.

AstraZeneca, MD Anderson Enter Collaboration to Help Improve Patient Outcomes in Ovarian/ Gynecologic Cancers

January 29, 2015 1:06 pm | News | Comments

AstraZeneca and The University of Texas MD Anderson Cancer Center today announced a multi-year, strategic research collaboration to conduct multiple, parallel clinical and clinically-related studies in ovarian and other gynecologic cancers with the aim of improving patient outcomes.

AstraZeneca’s BRILINTA® Meets Primary Endpoint in Both 60mg and 90mg Doses

January 14, 2015 8:19 am | News | Comments

The study assessed BRILINTA® (ticagrelor) tablets at either 60mg twice daily or 90mg twice daily plus low-dose aspirin for the secondary prevention of atherothrombotic events in patients who had experienced a heart attack one to three years prior to study start.

MedImmune Enters Licensing Agreement with Omnis Pharmaceuticals for Oncolytic Viruses in Immuno-Oncology

January 12, 2015 8:43 am | News | Comments

This agreement will allow MedImmune to combine key agents from its investigational immunotherapy portfolio with Omnis’ lead investigational oncolytic virus program, a genetically engineered strain of vesicular stomatitis virus (VSV).   


AstraZeneca Cancer Drug, Companion Test Approved

December 22, 2014 8:28 am | by LINDA A. JOHNSON, AP Business Writer | News | Comments

The FDA granted accelerated approval to the first in a new class of targeted drugs for ovarian cancer, Lynparza from British drugmaker AstraZeneca. The FDA also approved a companion diagnostic test from Myriad Genetics. The test is to be used to identify women most likely to benefit from the new medication.

European Commission Approves Lynparza™ for Advanced BRCA-Mutated Ovarian cancer

December 18, 2014 9:04 am | News | Comments

AstraZeneca today announced that the European Commission has granted Marketing Authorization for Lynparza™ capsules as the first therapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cance.

GlobalData: Patent Cliff Means Pharmaceutical Companies Will Lose $65B by 2019

December 10, 2014 9:24 am | News | Comments

Pharmaceutical companies will suffer an estimated $65B drop in sales by 2019 due to the patent expiries of several leading drugs, according to research and consulting firm GlobalData. The company’s report states that the drug makers hit hardest will include Otsuka, Eli Lilly, and AstraZeneca, with a significant proportion of losses coming in the Central Nervous System treatment sector.

Dynavax and AstraZeneca to Move Asthma Treatment Into Phase 2a Clinical Study

December 8, 2014 8:18 am | News | Comments

Dynavax Technologies and AstraZeneca signed an amendment to the existing Research Collaboration and License Agreement under which AstraZeneca will fully fund and Dynavax will conduct a Phase 2a safety and efficacy trial of AZD1419 in patients with asthma.

FDA Accepts New Drug Application for IRESSA

December 2, 2014 8:09 am | News | Comments

AstraZeneca today announced that the FDA has accepted for filing the NDA for IRESSA® (gefitinib) as a targeted monotherapy for the first line treatment of patients with advanced or metastatic epidermal growth factor receptor mutation positive (EGFRm) non-small cell lung cancer (NSCLC).

Eli Lilly and AstraZeneca Start Pivotal Clinical Trial for Patients with Early Alzheimer's Disease

December 1, 2014 8:22 am | News | Comments

Eli Lilly and and AstraZeneca today announced enrollment of the first patient into AMARANTH, a Phase II/III study of an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer's disease.

AstraZeneca to Expand Frederick, MA Biologics Manufacturing Center

November 24, 2014 8:46 am | News | Comments

AstraZeneca has announced plans to expand its biologics manufacturing center in Frederick, Md. The more than $200M project will increase production capacity at the facility to support AstraZeneca’s maturing pipeline, and will help position the company to keep pace with a growing demand for the development and use of biologics, which currently represent nearly 50% of AstraZeneca’s overall pipeline.

AstraZeneca and Isis Pharmaceuticals to Co-Develop Targeted Oligonucleotide Delivery Methods

November 13, 2014 8:23 am | News | Comments

Isis Pharmaceuticals and AstraZeneca today announced a strategic alliance to discover and develop novel delivery methods for antisense oligonucleotides. The new delivery approaches seek to target the desired tissue more effectively. The agreement builds on an existing collaboration between AstraZeneca and Isis Pharmaceuticals.

AstraZeneca Initiates Development Program for BRILINTA Reversal Agent

November 13, 2014 8:06 am | News | Comments

AstraZeneca has begun a pre-clinical development program to evaluate the ability of investigational antibody, MEDI2452, to rapidly and specifically reverse the antiplatelet effects of ticagrelor in rare emergency situations such as urgent surgery, or in the event of major bleeding.

Amgen and AstraZeneca Announce Brodalumab Phase III Results

November 12, 2014 9:01 am | News | Comments

AstraZeneca and Amgen today announced that AMAGINE-3TM, a pivotal, multi-arm Phase III trial evaluating two doses of brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis, met its primary endpoints when compared with both Stelara® (ustekinumab) and placebo at week 12

AstraZeneca to Divest Myalept to Aegerion

November 6, 2014 10:44 am | News | Comments

AstraZeneca has entered into a definitive agreement with Aegerion Pharmaceuticals, Inc. to divest Myalept™ (metreleptin for injection), an orphan product that is indicated to treat complications of leptin deficiency in patients with generalized lipodystrophy.

Isis Pharmaceuticals Earns $7.5M Milestone Payment from AstraZeneca

November 6, 2014 8:52 am | News | Comments

Isis Pharmaceuticals has earned a $7.5 million milestone payment, the first of two milestone payments totaling $15 million, from AstraZeneca for the advancement of ISIS-STAT3Rx, also referred to as AZD9150, in patients with advanced cancers.  

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.